ArticleScientific reports2022

Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors.

Takuma Matoba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.